Windtree's Istaroxime to be Featured in Plenary Session at Heart Failure Society of America 2025

Windtree Therapeutics announced that istaroxime was chosen for a plenary session presentation at the Heart Failure Society of America 2025 meeting. The presentation will feature interim data from the Phase 2 study of istaroxime in SEISMiC C, which aims to improve cardiac function and blood pressure in patients with cardiogenic shock. The company believes istaroxime has a promising profile for treating heart failure and cardiogenic shock, with consistent interim data and a potential to move forward with a global Phase 3 study.

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced that its drug candidate istaroxime has been chosen for a plenary session presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The presentation, titled "Safety and Efficacy of intravenous administration of istaroxime for 48 hours in patients with SCAI Stage C cardiogenic shock due to heart failure," will feature interim data from the Phase 2 SEISMiC C study [1].

The SEISMiC C study is a global trial evaluating istaroxime in patients with more severe cardiogenic shock (SCAI Stage C) than has been studied previously. The interim analysis included the first 20 patients enrolled in the study. No new safety concerns or excess arrhythmias were identified when istaroxime was combined with standard therapies. The effects on hemodynamic and echocardiographic measures appeared to be consistent with results seen in previous istaroxime studies [1].

Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. It increases myocardial contractility through inhibition of Na+/K+- ATPase and facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm [1].

Windtree Therapeutics believes that istaroxime has a promising profile for treating heart failure and cardiogenic shock. The consistent interim data and the potential to move forward with a global Phase 3 study are encouraging for the company. The selection for a plenary session at HFSA 2025 indicates recognition of the data's significance within the cardiology community [2].

References:

[1] https://www.biospace.com/press-releases/windtree-announces-istaroxime-phase-2-interim-analysis-in-scai-stage-c-cardiogenic-shock-patients
[2] https://www.stocktitan.net/news/WINT/windtree-announces-istaroxime-has-been-chosen-for-a-plenary-session-4byrc5wdj5mq.html